Navigation Links
MicroRNA regulation of tumor-killing viruses avoids unwanted viral pathology

Scientists have determined how to produce replication-competent viruses with key toxicities removed, providing a new platform for development of improved cancer treatments and better vaccines for a broad range of viral diseases.

Cellular microRNA molecules regulate the stability of mRNA in different cell types, and this newly-understood mechanism provides the possibility to engineer viruses for cell-specific inactivation. Cancer Research UK scientists at the University of Oxford, United Kingdom, with support from colleagues at Vrije Universiteit, Amsterdam, report that this approach can be used to regulate proliferation of adenovirus in a study published May 22 in the open-access journal PLoS Pathogens.

Adenovirus is a DNA virus widely used in cancer therapy but which causes hepatic disease in mice. Professor Len Seymour and colleagues found that introducing sites into the virus genome that are recognized by microRNA 122 leads to hepatic degradation of important viral mRNA, thereby diminishing the virus' ability to adversely affect the liver, while maintaining its ability to replicate in and kill tumor cells.

Tumor-killing replicating viruses are a hot topic in the biotherapeutics arena, with many clinical trials ongoing worldwide. That Professor Seymour's group set out to and has now defined a mechanism whereby wild type virus potency could be maintained in tumor cells but the virus could be 'turned off' in tissues vulnerable to pathology adds important information to the current base of knowledge.

"This approach is surprisingly effective and quite versatile. It could find a range of applications in controlling the activity of therapeutic viruses, both for cancer research and also to engineer a new generation of conditionally-replicating vaccines, where the vaccine pathogen is disabled in its primary sites of toxicity," Professor Seymour says.

The present study was intended mainly to explore and demonstrate the potential of this new mechanism to regulate virus activity. Although the current tumor-killing virus is useful in mice, transfer of the technology into the clinical setting will require re-engineering of the virus to overcome virus pathologies seen in humans, and it will be at least two years before this can be tested in the clinics.


Contact: Emma Gilgunn-Jones
Public Library of Science

Related medicine news :

1. Exiqon Announces New Grant Program for MicroRNA Research
2. Throwing the micro switch: MicroRNA may link smoking risk gene to neurobiology of addiction
3. InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer
4. MicroRNA undermines tumor suppression
5. MicroRNAs make for safer cancer treatments
6. Gladstone scientists identify single microRNA that controls blood vessel development
7. Putting microRNAs on the stem cell map
8. Need microRNA processing? Get Smad
9. MicroRNA controls expression of oncogenes
10. MicroRNAs appear essential for retinal health
11. MicroRNAs, EMT and cancer progression
Post Your Comments:
(Date:12/1/2015)... , ... December 01, 2015 , ... ... 1980s we have seen vast improvements in scientific research and discoveries, leading us ... providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform edition ...
(Date:12/1/2015)... ... December 01, 2015 , ... The ... been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s first portable ... Meeting from November 29 to December 4, 2015. , MED-TAB is expected ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... must mark the film for accurate interpretation by the radiologist. The marking utensils ... inventor from Sacramento, Calif., has found a way to alleviate this problem. , ...
(Date:12/1/2015)... San Francisco, CA (PRWEB) , ... December 01, ... ... The Behavioral Health Center of Excellence (BHCOE) today announced that the organization has ... based in San Francisco, with a Distinguished Award. The award celebrates exceptional special ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, ... in the United States. Clarity is a Superior Dual Wavelength Platform which combines ... single platform that is easy to own and operate. , For over a ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... -- CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical ... that it has reached its enrollment target of 400 ... trial of aldoxorubicin in patients with previously treated soft ... in Q1 2016. The Phase 3 trial is a randomized, ... from the FDA at 79 sites in ...
(Date:12/1/2015)... Dec. 1, 2015  InCarda Therapeutics, Inc. (InCarda), a ... of therapies for cardiovascular conditions via the inhalation route, ... in Australia . InCarda is planning ... Australia in the first half of ... medical centers in Adelaide and ...
(Date:12/1/2015)... , Dec. 1, 2015  Booth #3506 – Claymount is ... the annual meeting of the Radiological Society of ... this year. Based in the Netherlands ... Varian Medical Systems (NYSE: VAR ) and is one ... chambers and solid state automatic exposure control systems for controlling ...
Breaking Medicine Technology: